Pharmaceutical Mail. Second medical use patents, additional protection for orphans and some interpretations of the Bolar clause are perceived by the European Generics and Biosimilars Association (EGA) as a threat to the activity of this industry in Europe. The EGA held its 11th Legal Affairs Forum at the end of March in Brussels, in which "the complex interrelationship" that exists "between intellectual property and regulation" would have been evidenced, for whose conflicts "many times there is no single solution," he points out. to CF Sergio Napolitano, director of Legal Affairs and Commerce of the EGA.

READ MORE